TPST TPST
Company Profile ↓Company Overview
TPST (TPST) is a publicly traded company listed on with a market capitalization of $4.48M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -87.79% |
| 6 Months: | -62.06% |
| 3 Months: | -57.47% |
| 1 Month: | -7.74% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.84 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 92.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 84.00K | 56.00K | - | 81.00K | 55.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.94M | 7.97M | 3.60M | 4.08M | 27.72M |
| Operating Income | -6.92M | -7.65M | -9.60M | -12.40M | -16.81M | -17.17M | -17.77M | -21.44M | -18.24M | -18.96M | -14.59M | -17.93M | -9.41M | -4.39M | -4.99M | -7.81M | -10.66M | -10.16M | -11.75M | -12.13M | -5.24M | 5.43M | -5.13M | -6.79M | -7.74M | - | -8.16M | -8.77M | -8.77M | -7.58M | -7.47M | -6.59M | -7.97M | -9.58M | -10.55M | -10.94M | -7.97M | -3.60M | -4.08M | -27.72M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -10.63M | -7.76M | -3.44M | -3.96M | -27.64M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 161.00K | 46.00K | 0 | 0 | 0 |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -10.86M | -7.87M | -3.51M | -4.02M | -27.70M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -6.89M | -7.81M | -9.89M | -12.92M | -17.21M | -17.49M | -17.92M | -21.76M | -18.57M | -19.29M | -14.89M | -18.19M | -9.37M | -4.26M | -4.85M | -7.54M | -10.37M | -9.87M | -11.63M | -12.00M | -5.23M | -5.43M | -5.36M | -7.06M | -8.11M | -28.30M | -8.49M | -9.17M | -8.95M | -7.64M | -7.58M | -6.79M | -7.90M | -9.57M | -10.56M | -10.86M | -7.87M | -3.51M | -4.02M | -27.70M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -10.55 | -7.63 | -1.21 | - | -1.18 | -0.79 | -0.66 | -0.55 | -0.54 | -0.48 | -4.62 | -5.52 | -5.32 | -41.08 | -2.07 | -0.79 | - | -2.53 |
| R&D Expense | 3.26M | 4.65M | 4.53M | 5.33M | 5.75M | 4.02M | 4.00M | 5.96M | 5.99M | 4.99M | 5.76M | 5.00M | 4.02M | 2.62M | 2.39M | 1.68M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 277.00K | 653.00K | 295.00K | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 34.64M | 29.16M | 42.03M | 26.57M |
| Operating Income | -13.53M | -29.13M | -47.93M | -72.00M | -81.01M | -84.33M | -26.87M | -45.40M | -19.30M | - | -34.64M | -29.16M | -42.03M | -26.57M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -33.45M | -27.66M | -40.14M | -25.79M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | 1.62M | 1.45M | 1.32M | 207.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -35.71M | -29.49M | -41.84M | -26.26M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Net Income | -13.51M | -29.04M | -49.52M | -73.22M | -82.26M | -84.58M | -27.19M | -44.57M | -19.21M | - | -35.71M | -29.49M | -41.84M | -26.26M |
| Diluted EPS | - | - | - | - | - | - | - | - | -41.03 | - | -40.17 | -24.83 | -19.50 | -6.33 |
| R&D Expense | 6.32M | 15.80M | 21.78M | 18.43M | 21.64M | 18.34M | - | - | - | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 4.58M | 32.81M | 47.55M | 65.57M | 138.61M | 122.54M | 19.81M | 84.07M | 74.97M | 22.86M | - | 46.09M | 51.60M | 41.49M | 16.93M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | 32.95M | 40.36M | 31.47M | 8.27M |
| Cash & Equivalents | 4.54M | 14.78M | 18.08M | 6.41M | 43.22M | 43.93M | 17.58M | 73.29M | 62.48M | 18.82M | - | 31.23M | 39.23M | 30.27M | 7.71M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | 15.00M | 450.00K | 0 | - | - |
| Total Liabilities | 762.00K | 2.09M | 5.84M | 10.25M | 11.76M | 14.32M | 4.83M | 10.95M | 15.10M | 4.95M | - | 27.98M | 24.84M | 22.36M | 10.26M |
| Current Liabilities | 675.00K | 2.09M | 5.77M | 10.17M | 11.24M | 13.21M | 4.09M | 9.82M | 12.52M | 3.22M | - | 7.28M | 9.41M | 14.22M | 3.31M |
| Long Term Debt | - | - | - | - | - | - | 599.00K | 383.00K | 168.00K | 61.00K | 15.07M | 10.37M | 6.26M | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | 22.11M | 20.66M | 15.37M | 8.14M |
| Total Equity | -2.38M | 30.72M | 41.70M | 55.33M | 126.85M | 108.22M | -130.69M | 70.95M | -50.36M | -68.79M | - | 18.11M | 26.77M | 19.13M | 6.67M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 809.12K | 1.70M | 3.38M | 4.93M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -18.09M | -30.59M | -50.29M | -61.73M | -20.34M | -23.65M | -41.22M | -19.02M | - | -31.07M | -27.36M | -33.03M | -26.82M |
| Investing Cash Flow | - | -11.02M | -32.79M | -38.29M | 8.29M | 458.00K | 1.93M | 3.99M | -6.00K | - | -562.00K | -170.00K | -435.00K | 0 |
| Financing Cash Flow | - | 32.41M | 51.71M | 125.39M | 54.15M | -4.46M | 77.74M | 26.94M | 34.60M | - | 11.40M | 35.60M | 24.50M | 4.26M |
| Capital Expenditure | -849.00K | -719.00K | -2.80M | -5.23M | -2.59M | -4.00K | -36.00K | -397.00K | -50.00K | -135.00K | -562.00K | -170.00K | -435.00K | - |
| Free Cash Flow | - | -18.81M | -33.39M | -55.52M | -64.32M | -20.34M | -23.68M | -41.62M | -19.07M | - | -31.63M | -27.53M | -33.46M | -26.82M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | -20.23M | 8.07M | -8.96M | -22.56M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | -25,992.4% | -12,406.1% | -28,585.1% | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | -26,432.9% | -12,597.2% | -28,670.5% | - | - | - | - | - | - | - | - |
| ROE % | -44.0% | -69.6% | -89.5% | -57.7% | -76.0% | 64.7% | -38.3% | 88.5% | 27.9% | - | -197.2% | -110.2% | -218.8% | -393.9% |
| ROCE % | -44.0% | -69.7% | -86.5% | -56.5% | -74.1% | -536.4% | -36.2% | -72.7% | -98.3% | - | -89.3% | -69.1% | -154.1% | -195.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TPST
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage depletion and immune reset for autoimmu…
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
Advancing a pipeline of in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD7-targeted mRNA/LNP delivery approachLead candidate TPST-4003 combines proprietary CD7-targeted mRNA/LNP delivery with a c…
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”) today announced the appointment of two independent directors, Drake Richey and John Yee, MD, MPH to its Board…
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
BRISBANE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, to…
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children’s Applied Gene and Cell Therapy Center (“AGCTC”) as Lead Manu…
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
100% complete response (“CR”) rate among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 dual-targeting CD19/BCMA CAR-T across two ongoing Phase 1 trials (REDEEM-1 and POEMS-1)Favorable safety profile with no Grade >3 …
TPST — Frequently Asked Questions
What is the current share price of TPST?
As of 2026-08-05 17:25 PDT, TPST trades at $0.91 on NASDAQ/NYSE. Its 52-week range is $0.86 to $11.83.
What is the market capitalisation of TPST?
TPST has a market capitalisation of $4.48M on NASDAQ/NYSE.
What is the P/E ratio of TPST?
TPST trades at a trailing price-to-earnings (P/E) ratio of -0.14. Its price-to-book (P/B) ratio is 0.67.
Is TPST a good stock to buy?
This page provides a data-driven analysis of TPST, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.